Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Biochem Soc Trans ; 35(Pt 5): 1325-8, 2007 Nov.
Article in English | MEDLINE | ID: mdl-17956343

ABSTRACT

In spite of effective antibiotics to treat TB (tuberculosis) since the early 1960s, we enter the new millennium with TB, currently the leading cause of death from a single infectious agent, killing more than three million people worldwide each year. Thus an understanding of drug-resistance mechanisms, the immunobiology of cell wall components to elucidate host-pathogen interactions and the discovery of new drug targets are now required for the treatment of TB. Above the plasma membrane is a classical chemotype IV PG (peptidoglycan) to which is attached the macromolecular structure, mycolyl-arabinogalactan, via a unique diglycosylphosphoryl bridge. This review will discuss the assembly of the mAGP (mycolyl-arabinogalactan-peptidoglycan), its associated glycolipids and the site of action of EMB (ethambutol), bringing forward a new era in TB research and focus on new drugs to combat multidrug resistant TB.


Subject(s)
Antitubercular Agents/chemistry , Cell Wall/metabolism , Galactans/biosynthesis , Lipopolysaccharides/biosynthesis , Mycobacterium tuberculosis/metabolism , Galactans/metabolism , Lipopolysaccharides/metabolism , Mycobacterium tuberculosis/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL
...